Table 1:

Common Prostate Cancer Risk Stratification Systems Based on Clinicopathologic Features

System	Criteria
	Low Risk	Intermediate Risk	High Risk
D'Amico / AUA	All of: PSA < 10 ng/mL, and Gleason score ≤ 6, and Clinical stage T1-T2a, and Asymptomatic for metastases	All of: PSA 10–20 ng/mL, and Gleason score 7, and Clinical stage T2b, and Asymptomatic for metastases	One or more of: PSA > 20 ng/mL Gleason score ≥ 8 Clinical stage of T2c-3A Symptomatic for metastases
NCCN	All of: PSA < 10 ng/mL, and Gleason score 2–6, and Clinical stage T1–T2a, and	All of: PSA > 10–20 ng/mL, and Gleason score 7, and Clinical stage T2b or T2c, and	One or more of: PSA > 20 ng/mL Gleason score 8–10 Clinical stage T3a Not very high risk
	Very low risk PSA < 10 ng/mL, and Gleason score ≤ 6, and Clinical stage T1c, and Fewer than 3 positive biopsy cores and ≤ 50% cancer in each core	Not low risk	Very high risk Clinical stage T3b-4

Abbreviations: AUA, American Urological Association; NCCN, National Comprehensive Cancer Network; PSA, prostate-specific antigen.

Source: Rodrigues et al, 2012.¹⁴